Danaher Corporation Asset Resilience Ratio
Danaher Corporation asset resilience ratio. Danaher Corporation (DHR) has an Asset Resilience Ratio of 1.91% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Danaher Corporation to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Danaher Corporation (2009–2024)
Asset resilience ratio of Danaher Corporation from 2009 to 2024. This chart shows how Danaher Corporation's Asset Resilience Ratio has changed over time. Read DHR total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Danaher Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Danaher Corporation's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $1.53 Billion | 1.91% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $1.53 Billion | 1.91% |
Asset Resilience Insights
- Limited Liquidity: Danaher Corporation maintains only 1.91% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Danaher Corporation Industry Peers by Asset Resilience Ratio
Compare Danaher Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Vijaya Diagnostic Centre Limited
NSE:VIJAYA |
Diagnostics & Research | 15.15% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Danaher Corporation Asset Resilience Ratio by Year (2009–2024)
Danaher Corporation asset resilience ratio by year from 2009 to 2024. The table below shows the annual Asset Resilience Ratio data for Danaher Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.68% | $2.08 Billion | $77.54 Billion | -4.26pp |
| 2023-12-31 | 6.94% | $5.86 Billion | $84.49 Billion | -0.17pp |
| 2022-12-31 | 7.11% | $6.00 Billion | $84.35 Billion | +4.00pp |
| 2021-12-31 | 3.11% | $2.59 Billion | $83.18 Billion | -4.82pp |
| 2020-12-31 | 7.92% | $6.04 Billion | $76.16 Billion | -24.15pp |
| 2019-12-31 | 32.07% | $19.91 Billion | $62.08 Billion | +30.43pp |
| 2018-12-31 | 1.65% | $787.80 Million | $47.83 Billion | +0.30pp |
| 2017-12-31 | 1.35% | $630.30 Million | $46.65 Billion | -0.78pp |
| 2016-12-31 | 2.13% | $963.70 Million | $45.30 Billion | -- |
| 2015-12-31 | 0.00% | $0.00 | $48.22 Billion | -- |
| 2014-12-31 | 0.00% | $0.00 | $36.99 Billion | -- |
| 2013-12-31 | 0.00% | $0.00 | $34.67 Billion | -- |
| 2012-12-31 | 0.00% | $0.00 | $32.94 Billion | -- |
| 2011-12-31 | 0.00% | $0.00 | $29.95 Billion | -- |
| 2010-12-31 | 0.00% | $0.00 | $22.22 Billion | -- |
| 2009-12-31 | 0.00% | $0.00 | $19.60 Billion | -- |
About Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the deve… Read more